The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.
Br J Cancer
; 92(9): 1599-610, 2005 May 09.
Article
en En
| MEDLINE
| ID: mdl-15870830
ABSTRACT
Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Imagen por Resonancia Magnética
/
Inhibidores de la Angiogénesis
/
Neoplasias
/
Antineoplásicos
Tipo de estudio:
Diagnostic_studies
/
Evaluation_studies
/
Guideline
Idioma:
En
Revista:
Br J Cancer
Año:
2005
Tipo del documento:
Article
País de afiliación:
Reino Unido